Significant progress has been made in genomic diagnostics and biomarker identification to support personalized medicine. SumHealth partnered with Nucleus Genomics to broaden access to whole-genome sequencing, facilitating preventive care through cheek swab-based screenings covering over 2,000 disorders. Diagnostic tools like Inflammatix’s TriVerity test outperform conventional biomarkers in infection and sepsis severity assessments. Additionally, novel platforms enable precise quantification of nucleic acids and multiplex pathogen detection directly from blood. These innovations are enhancing early disease detection and guiding targeted therapies across clinical settings.